Saturday, September 27, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Helmerich & Payne: Analyst Upgrade Fuels Recovery Hopes

Dieter Jaworski by Dieter Jaworski
September 27, 2025
in Analysis, Energy & Oil, Turnaround
0
Helmerich, Payne Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

A single analyst upgrade has provided a much-needed boost to the beleaguered shares of drilling specialist Helmerich & Payne. Despite a challenging year that has left its stock deep in negative territory, a recent rating increase from Barclays suggests a potential shift in market sentiment. The critical question remains: can the company overcome prevailing skepticism?

Solid Financials Amid Market Caution

Even with the positive news, the broader analyst consensus maintains a “Hold” rating. Average price targets remain cautious, hovering between $20.80 and $22.45. This reflects the general wariness in the market, which is also evident in the “Fear” reading of the Fear & Greed Index.

Helmerich & Payne’s strongest asset may be its resilient financial position. The company is well-equipped for volatility, boasting an investment-grade credit rating, $187 million in liquid assets, and access to an untapped $950 million credit facility. Its accelerated debt repayment schedule further highlights a commitment to financial stability.

Barclays Provides a Catalyst

The catalyst for the recent uptick came from investment bank Barclays. In late September, the bank raised its rating for Helmerich & Payne from “Equalweight” to “Overweight.” More significantly, it substantially increased its price target from $17 to $25. The market responded immediately, with the stock advancing over 3% following the announcement. Such a decisive move from a major institution often indicates a reassessment of a company’s prospects, particularly within the tough offshore drilling sector.

Should investors sell immediately? Or is it worth buying Helmerich, Payne?

A Tale of Two Segments: Quarterly Results Reveal Divergence

The company’s August quarterly report painted a mixed picture. While Helmerich & Payne posted a GAAP net loss of $163 million, this was primarily due to a one-time impairment charge of $173 million. Excluding this special item, the adjusted earnings per share came in at $0.22, surpassing analyst forecasts. Operational strength was clearly demonstrated by a impressive 49.2% revenue increase to $1.04 billion.

A deeper look at segment performance reveals the underlying challenges:
* The core North American operations reported improved operating results.
* Conversely, the international division experienced a significantly larger loss.

The Path Ahead

The key uncertainty is whether the momentum from the analyst upgrade can be sustained. The fundamental split between robust North American demand and persistent international market problems continues to be the primary hurdle. Upcoming industry conferences will be closely watched for a convincing global growth strategy from CEO John Lindsay. For investors, the dilemma is determining if this marks the beginning of a genuine trend reversal or merely a short-lived rebound.

Ad

Helmerich, Payne Stock: Buy or Sell?! New Helmerich, Payne Analysis from September 27 delivers the answer:

The latest Helmerich, Payne figures speak for themselves: Urgent action needed for Helmerich, Payne investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 27.

Helmerich, Payne: Buy or sell? Read more here...

Tags: Helmerich, Payne
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Iovance Stock
Analysis

Iovance Biotherapeutics Shares Plunge on Weak Earnings and Technical Breakdown

September 27, 2025
Inmune Bio Stock
Analysis

Inmune Bio Shares Continue Downward Trajectory Amidst Weak Fundamentals

September 27, 2025
Nike Stock
Analysis

Nike Faces Critical Test as Quarterly Results Approach

September 27, 2025
Next Post
D-Wave Quantum Stock

D-Wave Quantum Shares Flash Caution After Spectacular Run

Harvard Bioscience Stock

Harvard Bioscience Shares Face Persistent Downtrend Amid Strategic Shifts

Procter & Gamble Stock

Procter & Gamble Shares Face Mounting Pressure as Sentiment Sours

Recommended

Promising Results of Phase 2 Trial for Paltusotine in Treating Carcinoid Syndrome

2 years ago
Finances

Financial Experts Pessimistic about ASML Holding Amid Unusual Options Activity

2 years ago
DrugRetailers Trading online

BuildABear Workshop Sees Boost in Shares After Strong Q4 Results and Positive Outlook

2 years ago
Beyond Meat Stock

Beyond Meat Shares Plummet as Crisis Deepens

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

FS KKR Capital: A Battle for Stability Amid Investor Skepticism

EssilorLuxottica Shares Gain Momentum on Dual Regulatory Victories

Robinhood Shares Retreat Following S&P 500 Milestone

Salesforce Stock: Navigating the Divide Between AI Ambition and Market Realities

Procter & Gamble Shares Face Mounting Pressure as Sentiment Sours

Harvard Bioscience Shares Face Persistent Downtrend Amid Strategic Shifts

Trending

Iovance Stock
Analysis

Iovance Biotherapeutics Shares Plunge on Weak Earnings and Technical Breakdown

by Dieter Jaworski
September 27, 2025
0

Iovance Biotherapeutics experienced a severe sell-off in the most recent trading session, with its shares plummeting 4.7...

Inmune Bio Stock

Inmune Bio Shares Continue Downward Trajectory Amidst Weak Fundamentals

September 27, 2025
Nike Stock

Nike Faces Critical Test as Quarterly Results Approach

September 27, 2025
FS KKR Capital Stock

FS KKR Capital: A Battle for Stability Amid Investor Skepticism

September 27, 2025
Essilor International Stock

EssilorLuxottica Shares Gain Momentum on Dual Regulatory Victories

September 27, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Iovance Biotherapeutics Shares Plunge on Weak Earnings and Technical Breakdown
  • Inmune Bio Shares Continue Downward Trajectory Amidst Weak Fundamentals
  • Nike Faces Critical Test as Quarterly Results Approach

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com